Trial Profile
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs SPK 8016 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Spark Therapeutics
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 21 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Mar 2023.
- 21 Feb 2023 Status changed from recruiting to active, no longer recruiting.